Fol News

Tutti gli approfondimenti
Tutte le notizie

AKAO Achaogen Inc( NASDAQ:AKAO)

ACHAOGEN, INC. (NASDAQ:AKAO) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On December 27, 2018, Achaogen, Inc. (the “Company”) entered into a License Confirmation Agreement and a Redemption Agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”) (together, the “2018 Agreements”) in connection with the amendment of certain provisions of the Grant Agreement (the “Grant Agreement”) and the Letter Agreement (the “Letter Agreement”) each previously entered into between the Company and the Gates Foundation and dated as ofMay 4, 2017.The 2018 Agreements were entered into following the de-prioritization of antibody work by the Company, which was the focus of the Company’s collaboration with the Gates Foundation.Among other things, the 2018 Agreements (a) terminated the Company’s obligations to conduct mutually agreed upon work, including work related the Company’s platform technology to develop and launch a product intended to prevent neonatal sepsis, (b) terminated the obligations of the Company to discover drug candidates intended to prevent neonatal sepsis and the obligation of the Gates Foundation to fund approximately $7.1 million in grants not yet received by the Company and (c) granted the Gates Foundation a non-exclusive license to intellectual property developed by the Company to the Grant Agreement and Letter Agreement in specified developing countries.

The Redemption Agreement also provided for the redemption by the Company of the 407,331 shares of the Company’s common stock (the “Gates Shares”) purchased by the Gates Foundation to a Common Stock Purchase Agreement between the Company and the Gates Foundation dated as of May 4, 2017 (the “Purchase Agreement”) for an aggregate redemption price of $5,737,082. The Company paid for the redemption of the Gates Shares with the unused portion of the restricted cash received by the Company to the original purchase of the Gates Shares under the Purchase Agreement.No unrestricted cash of the Company was used to fund the redemption.

The foregoing is only a summary description of the terms of the License Confirmation Agreement and Redemption Agreement, does not purport to be complete and is qualified in its entirety by reference to the License Confirmation Agreement and Redemption Agreement, which will be filed as exhibits to the Company’s next Annual Report on Form 10-K for the year ended December 31, 2018.
 
inversione solo sopra 1.63
indicatori scarichi, vediamo se questa settimana brekka la sma 50
 

Allegati

  • akao.png
    akao.png
    31,3 KB · Visite: 203
azz.....si è fermata proprio li....a contatto con la kjiun sen, gli indicatori sono ancora scarichi, vediamo se domani brekka o si prende una pausa,
in caso di break primo target 2.75
 

Allegati

  • sc.png
    sc.png
    31,7 KB · Visite: 193
Io mi accontento di 1,8 circa come.primo step
 
lo sapevo porca putt
 
azz... ma ti fai spaventare da un -3 in apertura??.....anni fa ero andato alla presentazione di un corso di trading di banca sella di una giornata e l'unica cosa che ho imparato è che la prima ora è quella dei polli, non so se ci hai mai fatto caso ma spessissimo i titoli che aprono negativi chiudono positivi e viceversa.....in poche parole nella prima ora tirano l'amo per vedere chi abbocca :eek:
cmq resistenza a 2.02 se bucata primo target 2.75 mentre a 3.07 c'è il primo gap da chiudere, il secondo è a 12 :D per chi saprà resistere :p
 

Allegati

  • akao.png
    akao.png
    31,7 KB · Visite: 158
renna63 ha scritto:
azz... ma ti fai spaventare da un -3 in apertura??.....anni fa ero andato alla presentazione di un corso di trading di banca sella di una giornata e l'unica cosa che ho imparato è che la prima ora è quella dei polli, non so se ci hai mai fatto caso ma spessissimo i titoli che aprono negativi chiudono positivi e viceversa.....in poche parole nella prima ora tirano l'amo per vedere chi abbocca :eek:
cmq resistenza a 2.02 se bucata primo target 2.75 mentre a 3.07 c'è il primo gap da chiudere, il secondo è a 12 :D per chi saprà resistere :p
Clicca per espandere...
e ma ero entrato un po troppo alto a 1,53 le ho ridate a 1,64 e mi son rimesso alla stessa cifra , naturalemnte cucccucaz che mi servirono
poi iniziavo ad averne troppe in ptf per le mie capacita:rolleyes:
 
Avio ha scritto:
e ma ero entrato un po troppo alto a 1,53 le ho ridate a 1,64 e mi son rimesso alla stessa cifra , naturalemnte cucccucaz che mi servirono
poi iniziavo ad averne troppe in ptf per le mie capacita:rolleyes:
Clicca per espandere...

prese un cippetto di queste oggi
 
Avio ha scritto:
mah non so su st continuano a scrivere che se non si finanziano in qualche modo son kaput , anche per questo sono uscito presto
Clicca per espandere...

per me questo domani reagisce
il grafico è come una molla compressa
 
vendute a 1,48
spero di non dovermi pentire
 
Riprese se passa 1,48 dovrebbe accelerare
 
Avio ha scritto:
mi son perso un passaggio:o

fosse ancora vivo(follisticamente parlando) ti appipperebbe un bel PAPERTRADER :D
Clicca per espandere...

mah le ho riprese a 1,405 perché son convinto che alla prossima sparata le portano a 2 ,
fra l' altro vedo che anche tu le hai riprese e non penso che vuoi uscire ad 1,5
 
Okkio che si muove, buona una chiusura sopra 1.47
 
Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield
GlobeNewswire•February 14, 2019

-- Plazomicin may be well-suited to play a critical role in biodefense preparedness --

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has responded to a Request for Information (RFI) regarding antibacterial products with the potential to treat resistant biothreat pathogens. The RFI was solicited by the Assistant Secretary for Preparedness and Response (ASPR) / the Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield.

The RFI specifically requested information on availabilities and capabilities for procuring, stockpiling and investing in the ongoing development of antibiotic products for commercial use for treatment of multiple biodefense indications, including pneumonic plague and tularemia, for which plazomicin has demonstrated preclinical efficacy.

“We have continued to look for ways to expand our long and collaborative partnership with BARDA,” said Blake Wise, Achaogen’s Chief Executive Officer. “Project BioShield’s mission of accelerating public health preparedness is profoundly important. We believe that plazomicin is well-suited to playing a critical role in biodefense preparedness and we are hopeful that industry responses to this RFI will encourage BARDA to progress to a Request for Proposal (RFP).”

Plazomicin, marketed as ZEMDRI® in the United States, was approved by the U.S. Food and Drug Administration (FDA) in June 2018 for the treatment of adults with complicated urinary tract infections, including pyelonephritis, due to certain Enterobacteriaceae. Plazomicin was developed through FDA approval with support from BARDA which provided $124.4 million in research and development funding over the lifetime of the program, starting in 2010.

Plazomicin is an aminoglycoside antibiotic designed to overcome the most clinically relevant mechanisms that inactivate older members of the class, such as gentamicin. Gentamicin is a mainstay of therapy for the treatment of threat pathogens such as Yersinia pestis (e.g. pneumonic plague) and Franciscella tularensis (e.g. pneumonic tularemia). Along with anthrax, these pathogens are considered “Category A” threats by the Centers for Disease Control and Prevention, representing the highest level threat due to ease of dissemination and transmission, and high associated mortality.

There is an increasing risk of having to confront resistant outbreaks of Y. pestis and F. tularensis as transmissible resistance in community and hospital pathogens increases. “Our appropriate focus on stewardship and targeted delivery of the newest drugs to address only the most resistant pathogens has created a dynamic that could severely hinder response time, by months or even years, if there is a sudden outbreak of a resistant form of a disease such as pneumonic plague,” said Dr. Ryan Cirz, Achaogen’s Vice President of Research. ”A public-private partnership to better prepare for such an event would be an exciting development.”

About the Antibiotic Resistance Project BioShield
Project BioShield is a comprehensive effort involving the U.S. Department of Health and Human Services (HHS), its component agencies, and other partner federal agencies to speed the research, development, acquisition and availability of medical countermeasures, such as antibiotics, to improve the government’s preparedness for and ability to counter various threats to public health. Federal agencies use Requests for Information (RFI) as a form of market research. During the RFI process, component agencies, such as ASPR/BARDA, solicit information from stakeholders regarding capabilities to address a threat. Depending on the results of the RFI process, a Request for Proposals (RFP) may be put forth to solicit proposals from stakeholders to specifically address the threat. If the agency accepts the proposal, the stakeholder enters into a contract with the government. Historically, Project BioShield contracts include one or more of the following: government procurement of product for countermeasures; support of development activities to gain approval for use and/or expansion of use in additional populations; support for additional manufacturing and supply chain development to increase both volume and robustness of supply. RFI reference solicitation number SS_BARDA-2019-01A
 
Devi accedere o registrarti per poter rispondere.
Indietro